Severe Asthma - Epidemiology Forecast - 2032

This ‘Severe Asthma - Epidemiology Forecast-2032' report delivers an in-depth understanding of severe asthma, historical and forecasted epidemiology as well as severe asthma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Severe Asthma Disease Understanding

Asthma is the most common chronic respiratory illness worldwide. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), leading to variable and excessive airway narrowing.

It is a heterogeneous disease characterized by reversible bronchial obstruction with recurrent wheezing and airflow obstruction as its hallmark. Other features associated with asthma, such as epithelial sloughing, mucous hypersecretion, bronchial hyper-responsiveness, and mucosal edema, are variable and usually depend on the age of onset, associated comorbidities, laboratory abnormalities, and reversibility of airflow obstruction.

The characteristic symptoms of asthma include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate. These symptoms typically worsen at night and after exposure to triggers, such as environmental allergens, upper respiratory tract infections, tobacco, cold air, and exercise.

NAEPP/EPR guidelines broadly classify asthma into intermittent or persistent. Persistent asthma is further sub-divided based on severity into mild, moderate, and severe.

NIH Guidelines for diagnosis and treatment of asthma characterize severe persistent asthma by symptoms that tend to be continual, cause limitations in physical activity, and are generally associated with frequent and severe exacerbations. Most individuals with severe asthma have frequent nighttime symptoms and persistent airflow obstruction with a forced expiratory volume (FEV1) of less than 60% predicted before treatment. Based on the response to treatment, severe asthma is further classified into type-2 inflammation and non-type-2 inflammation. Type-2 inflammation includes allergic asthma and eosinophilic asthma (or e-asthma) while non-type-2 inflammation includes non-eosinophilic asthma.

Most people with asthma can manage their symptoms well with the usual medicines like a preventer inhaler and a reliever inhaler, but severe asthma is difficult to control the disease.

Severe Asthma Diagnosis

Severe asthma may be defined not only by difficult-to-control airway disease symptoms but also by the severity of abnormalities and measurements of pulmonary function. Careful physiologic characterizations of patients with well-defined severe asthma are lacking, making diagnosis difficult. In most cases, diagnosis depends on the symptoms and the response to treatment already being administered.

However, to establish a diagnosis of asthma, the clinician determines whether the episodic symptoms of airflow obstruction or airway hyperresponsiveness are present and whether airflow obstruction is at least partially reversible, measured by spirometry. Reversibility is determined by an increase in FEV1 of >200 mL and 12% from baseline measure after inhalation of short-acting b2-agonist (SABA).

Severe Asthma Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of asthma, severity-specific diagnosed prevalent cases of asthma, and type-specific diagnosed prevalent cases of severe asthma, the scenario of Severe Asthma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Severe Asthma Detailed Epidemiology Segmentation

• Total diagnosed prevalent cases of asthma in the 7MM were found to be approximately 42,612,876 cases in adults and 11,602,740 cases in the pediatric population in the year 2021. The diagnosed prevalent cases of Asthma are expected to rise significantly by 2032.
• The United States accounted for 5,189,648 and 20,868,845 diagnosed prevalent cases of pediatric and adult asthma, respectively in 2021.
• In 2021, the total reported diagnosed prevalent cases (adult+pediatric) of asthma in EU-5 countries were 21,034,152 cases which are expected to rise significantly by 2032.
• In 2021, the UK accounted for the highest number of asthma diagnosed prevalent cases (5,884,988), followed by France (4,117,330) among the EU-5 countries. In contrast, Spain accounts for the lowest number of cases of asthma diagnosed prevalent population in the EU-5.
• As per the analysis, in Japan, the intermittent, mild, moderate, and severe cases of asthma were observed to be 4,060,094, 854,757, 1,353,365, and 854,757 cases, respectively in 2021. The severity-specific cases are expected to change by 2032.

Scope of the Report

• The report covers a descriptive overview of severe asthma, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of severe asthma.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM, a total number of total diagnosed prevalent cases of asthma, severity-specific diagnosed prevalent cases of asthma, and type-specific diagnosed prevalent cases of severe asthma.

Report Highlights

• 11-Year Forecast of Severe Asthma
• The 7MM Coverage
• Total diagnosed prevalent cases of asthma
• Severity-specific diagnosed prevalent cases of asthma
• Type-specific diagnosed prevalent cases of Severe Asthma

Key Questions Answered

• What are the disease risk and burdens of Severe Asthma?
• What is the historical Severe Asthma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Severe Asthma at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population for Severe Asthma?
• Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Severe Asthma during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Severe Asthma report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Severe Asthma epidemiology forecast.
• The Severe Asthma epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Severe Asthma epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032